We have found previously that the tumor cell lines, Renca (a renal cancer) and MC38 (a colon tumor) which had been injected subcutaneously in mice, could be successfully treated with a combination therapy of an oligodeoxynucleotide (CpG1826) (injected intratumorally) and anti-CD137 antibody (injected intraperitoneally). Thus the combination treatment was expected to initiate a “danger” signal via TLR9 on immune cells, and the anti-CD137 was expected to further activate T cells. In the present study, we found that several other tumor types injected subcutaneously could also be successfully treated with this combination therapy. In addition, we wished to determine if the treatment could work as effectively in an orthotopic metastatic model, which is more physiologically relevant to cancer in humans. Renca was selected as we were familiar with injecting this orthotopically into the outer cortex of the kidney in mice, and it spontaneously metastasizes to lung and abdominal sites. We tested various routes of delivery of CpG combined with intraperitoneal delivery of anti-CD137. Orthotopic tumors were injected with CpG intratumorally, using ultrasound-guided delivery on multiple occasions, combined with anti-CD137 intraperitoneally. A reduction in primary tumor size was observed following intratumoral injection of CpG compared to other treatments. We found that there was a statistically significant increase in survival of mice with orthotopic Renca tumor following intratumoral injection of CpG. However, we determined that the most effective route of delivery of CpG was intravenous, which led to further significantly enhanced survival of mice when combined with anti-CD137 intraperitoneally, likely due to inhibition of metastatic disease. Our data supports future development of this combination therapy for cancer.
References
[1]
Jahrsdorfer B, Weiner GJ (2008) CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther 3: 27–32. doi: 10.1016/j.uct.2007.11.003
[2]
Furi I, Sipos F, Germann TM, Kalmar A, Tulassay Z, et al. (2013) Epithelial Toll-like receptor 9 signaling in colorectal inflammation and cancer: clinico-pathogenic aspects. World J Gastroenterol 19: 4119–4126. doi: 10.3748/wjg.v19.i26.4119
[3]
Li SY, Liu Y (2013) Immunotherapy of melanoma with the immune costimulatory monoclonal antibodies targeting CD137. Clin Pharmacol 5: 47–53. doi: 10.2147/cpaa.s46199
[4]
Vinay DS, Kwon BS (2012) Immunotherapy of cancer with 4-1BB. Mol Cancer Ther 11: 1062–1070. doi: 10.1158/1535-7163.mct-11-0677
[5]
Westwood JA, Haynes NM, Sharkey J, McLaughlin N, Pegram HJ, et al. (2009) Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice. Clin Cancer Res 15: 7624–7633. doi: 10.1158/1078-0432.ccr-09-2201
[6]
Killion JJ, Radinsky R, Fidler IJ (1998) Orthotopic models are necessary to predict therapy of transplantable tumors in mice. Cancer Metastasis Rev 17: 279–284. doi: 10.1023/a:1006140513233
[7]
Bibby MC (2004) Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 40: 852–857. doi: 10.1016/j.ejca.2003.11.021
[8]
Talmadge JE, Singh RK, Fidler IJ, Raz A (2007) Murine models to evaluate novel and conventional therapeutic strategies for cancer. Am J Pathol 170: 793–804. doi: 10.2353/ajpath.2007.060929
[9]
Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS (2011) Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer 11: 135–141. doi: 10.1038/nrc3001
[10]
Bianchi M, Sun M, Jeldres C, Shariat SF, Trinh QD, et al. (2012) Distribution of metastatic sites in renal cell carcinoma: a population-based analysis. Ann Oncol 23: 973–980. doi: 10.1093/annonc/mdr362
[11]
Westwood JA, Darcy PK, Guru PM, Sharkey J, Pegram HJ, et al. (2010) Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice. J Transl Med 8: 42. doi: 10.1186/1479-5876-8-42
[12]
Jager W, Moskalev I, Janssen C, Hayashi T, Awrey S, et al. (2013) Ultrasound-guided intramural inoculation of orthotopic bladder cancer xenografts: a novel high-precision approach. PLoS One 8: e59536. doi: 10.1371/journal.pone.0059536
[13]
Ota S, Geschwind JF, Buijs M, Wijlemans JW, Kwak BK, et al. (2013) Ultrasound-guided direct delivery of 3-bromopyruvate blocks tumor progression in an orthotopic mouse model of human pancreatic cancer. Target Oncol 8: 145–151. doi: 10.1007/s11523-013-0273-x
[14]
Lin LW, Lin XD, He YM, Gao SD, Xue ES (2003) Experimental study on ultrasound-guided intratumoral injection of “Star-99” in treatment of hepatocellular carcinoma of nude mice. World J Gastroenterol 9: 701–705.
[15]
Murphy GP, Hrushesky WJ (1973) A murine renal cell carcinoma. J Natl Cancer Inst 50: 1013–1025.
[16]
Krieg AM (2007) Development of TLR9 agonists for cancer therapy. J Clin Invest 117: 1184–1194. doi: 10.1172/jci31414
[17]
Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, et al. (2010) Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 63: 975–983. doi: 10.1016/j.jaad.2009.12.052
[18]
Zent CS, Smith BJ, Ballas ZK, Wooldridge JE, Link BK, et al. (2012) Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia. Leuk Lymphoma 53: 211–217. doi: 10.3109/10428194.2011.608451
[19]
Mason KA, Hunter NR (2012) CpG plus radiotherapy: a review of preclinical works leading to clinical trial. Front Oncol 2: 101. doi: 10.3389/fonc.2012.00101
[20]
Millward M, Underhill C, Lobb S, McBurnie J, Meech SJ, et al. (2013) Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. Br J Cancer 108: 1998–2004.
[21]
Amos SM, Pegram HJ, Westwood JA, John LB, Devaud C, et al. (2011) Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol Immunother 60: 671–683. doi: 10.1007/s00262-011-0984-8
[22]
Uno T, Takeda K, Kojima Y, Yoshizawa H, Akiba H, et al. (2006) Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med 12: 693–698. doi: 10.1038/nm1405
[23]
Teng MW, Swann JB, von Scheidt B, Sharkey J, Zerafa N, et al. (2010) Multiple antitumor mechanisms downstream of prophylactic regulatory T-cell depletion. Cancer Res 70: 2665–2674. doi: 10.1158/0008-5472.can-09-1574
[24]
Smith SE, Hoelzinger DB, Dominguez AL, Van Snick J, Lustgarten J (2011) Signals through 4-1BB inhibit T regulatory cells by blocking IL-9 production enhancing antitumor responses. Cancer Immunol Immunother 60: 1775–1787. doi: 10.1007/s00262-011-1075-6
[25]
Sin JI, Kim H, Ahn E, Jeon YH, Park WS, et al. (2013) Combined stimulation of TLR9 and 4.1BB augments Trp2 peptide vaccine-mediated melanoma rejection by increasing Ag-specific CTL activity and infiltration into tumor sites. Cancer Lett 330: 190–199. doi: 10.1016/j.canlet.2012.11.045
[26]
Wilmanns C, Fan D, O'Brian CA, Bucana CD, Fidler IJ (1992) Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer 52: 98–104. doi: 10.1002/ijc.2910520118
[27]
Wilmanns C, Fan D, Obrian C, Radinsky R, Bucana C, et al. (1993) Modulation of Doxorubicin sensitivity and level of p-glycoprotein expression in human colon-carcinoma cells by ectopic and orthotopic environments in nude-mice. Int J Oncol 3: 413–422. doi: 10.3892/ijo.3.3.413
[28]
Kuo TH, Kubota T, Watanabe M, Furukawa T, Kase S, et al. (1993) Site-specific chemosensitivity of human small-cell lung carcinoma growing orthotopically compared to subcutaneously in SCID mice: the importance of orthotopic models to obtain relevant drug evaluation data. Anticancer Res 13: 627–630.
[29]
Graves EE, Vilalta M, Cecic IK, Erler JT, Tran PT, et al. (2010) Hypoxia in models of lung cancer: implications for targeted therapeutics. Clin Cancer Res 16: 4843–4852. doi: 10.1158/1078-0432.ccr-10-1206
[30]
Hackl C, Man S, Francia G, Milsom C, Xu P, et al. (2013) Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 62: 259–271. doi: 10.1136/gutjnl-2011-301585
[31]
Devaud C, Westwood JA, John LB, Flynn JK, Paquet-Fifield S, et al. (2014) Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. Mol Ther 22: 18–27. doi: 10.1038/mt.2013.219
[32]
Ruggeri BA, Camp F, Miknyoczki S (2013) Animal models of disease: Pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem Pharmacol S0006-2952(13)00391-2. doi:10.1016/j.bcp.2013.06.020. [Epub ahead of print].
[33]
McMillin DW, Negri JM, Mitsiades CS (2013) The role of tumour-stromal interactions in modifying drug response: challenges and opportunities. Nat Rev Drug Discov 12: 217–228. doi: 10.1038/nrd3870
[34]
Ruggeri BA, Camp F, Miknyoczki S (2014) Animal models of disease: Pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem Pharmacol 87: 150–161. doi: 10.1016/j.bcp.2013.06.020
[35]
Kahn J, Tofilon PJ, Camphausen K (2012) Preclinical models in radiation oncology. Radiat Oncol 7: 223. doi: 10.1186/1748-717x-7-223
[36]
Norian LA, Kresowik TP, Rosevear HM, James BR, Rosean TR, et al. (2012) Eradication of metastatic renal cell carcinoma after adenovirus-encoded TNF-related apoptosis-inducing ligand (TRAIL)/CpG immunotherapy. PLoS One 7: e31085. doi: 10.1371/journal.pone.0031085
[37]
Pulkkanen KJ, Laukkanen JM, Fuxe J, Kettunen MI, Rehn M, et al. (2002) The combination of HSV-tk and endostatin gene therapy eradicates orthotopic human renal cell carcinomas in nude mice. Cancer Gene Ther 9: 908–916. doi: 10.1038/sj.cgt.7700519
[38]
Bult W, Kroeze SG, Elschot M, Seevinck PR, Beekman FJ, et al. (2013) Intratumoral administration of holmium-166 acetylacetonate microspheres: antitumor efficacy and feasibility of multimodality imaging in renal cancer. PLoS One 8: e52178. doi: 10.1371/journal.pone.0052178
[39]
Kudo-Saito C, Wansley EK, Gruys ME, Wiltrout R, Schlom J, et al. (2007) Combination therapy of an orthotopic renal cell carcinoma model using intratumoral vector-mediated costimulation and systemic interleukin-2. Clin Cancer Res 13: 1936–1946. doi: 10.1158/1078-0432.ccr-06-2398
[40]
Lou Y, Liu C, Lizee G, Peng W, Xu C, et al. (2011) Antitumor activity mediated by CpG: the route of administration is critical. J Immunother 34: 279–288. doi: 10.1097/cji.0b013e31820d2a05
[41]
Nierkens S, den Brok MH, Roelofsen T, Wagenaars JA, Figdor CG, et al. (2009) Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice. PLoS One 4: e8368. doi: 10.1371/journal.pone.0008368
[42]
von Beust BR, Johansen P, Smith KA, Bot A, Storni T, et al. (2005) Improving the therapeutic index of CpG oligodeoxynucleotides by intralymphatic administration. Eur J Immunol 35: 1869–1876. doi: 10.1002/eji.200526124
